Core Insights - Kenvue Inc. (NYSE:KVUE) is currently under scrutiny due to litigation concerns, but the overall sentiment from analysts suggests that long-term shareholders should not be overly worried [1][2] - The company operates in the consumer health products sector, offering well-known brands such as Tylenol, Motrin, Calpol, Neutrogena, and Band-Aid [2] Company Overview - Kenvue Inc. provides a range of consumer health products, including pain relief, allergy care, digestive support, wellness, and personal care [2] - The stock is currently at a 4.5% yield, and the company has new leadership in place [2] Analyst Sentiment - Jim Cramer believes that while there will be lawsuits, the situation is manageable and not as dire as perceived [1][2] - Cramer does not expect significant upside for Kenvue's stock in the near term, indicating a cautious outlook [2]

Verizon Communications Inc. (NYSE:VZ) is one of the stocks on Jim Cramer’s radar recently. When a caller mentioned that they have had a position in the stock for the past two years, Cramer commented: “I’m going to liberate you from Verizon. Nope, I don’t want you, I want you to scale out of Verizon. It does yield 6.7%.” Stock market reports printed on a sheet of paper. Photo by RDNE Stock Project on Pexels Verizon Communications Inc. (NYSE:VZ) provides wireless, broadband, and wireline services. The c ...

This post originally appeared in the First Trade newsletter. You can sign up for Business Insider's daily markets newsletter here. It may not feel like it, but 2025 has been a record year for retail traders. It's been even busier than 2021, when GameStop mania was at its peak. Compared to last year, retail activity is up 50%. That's likely indicative of more volatility in 2025, especially the nearly 20% drawdown from February to early April. Those shifting sands gave rise to investment strategies th ...

Core Insights - Madison Small Cap Fund experienced a challenging third quarter in 2025, with a decline of 1.3%, underperforming its benchmarks due to stock selection and a speculative market environment [1] Company Performance - Saia, Inc. (NASDAQ:SAIA) reported a one-month return of -13.67% and a 52-week loss of 53.76%, closing at $250.48 per share with a market capitalization of $6.673 billion as of November 20, 2025 [2] - In Q3 2025, Saia, Inc. announced revenue of $839.6 million, which remained relatively flat compared to Q3 2024 [4] Investment Strategy - Madison Small Cap Fund exited its position in Saia, Inc. during the third quarter due to a challenging macroeconomic environment for LTL pricing and operational issues related to geographic expansion [3] - The fund expressed a willingness to revisit the investment in the future if operating rates improve, highlighting the company's strong customer service focus and excellent business moat [3]

Core Insights - Madison Small Cap Fund experienced a challenging third quarter in 2025, with the fund down 1.3%, underperforming its benchmarks due to stock selection and a speculative market environment [1] Fund Performance - The Madison Small Cap Fund's performance was significantly impacted by a broad-based decline in the small-cap index [1] - The fund's top five holdings are highlighted as key picks for 2025 [1] Shake Shack Inc. Analysis - Shake Shack Inc. (NYSE: SHAK) reported a one-month return of -8.87% and a 52-week loss of 31.96%, closing at $83.70 per share with a market capitalization of $3.573 billion on November 20, 2025 [2] - The fund noted that Shake Shack's performance was affected by aggressive analyst expectations and concerns about the job market, which could impact future customer traffic [3] - Despite the challenges, the long-term outlook for Shake Shack remains positive, with potential for improved store-level margins [3] Financial Performance - Shake Shack Inc. reported total revenue of $367.4 million in Q3 2025, reflecting a year-over-year increase of 15.9% [4] - The company is not among the top 30 most popular stocks among hedge funds, with a decrease in hedge fund holdings from 39 to 34 [4]

Core Insights - Matrix Asset Advisors reported a recovery in the stock market with a gain of +8.12% in Q3 2025 and +14.83% year-to-date [1] - The Matrix Large Cap Value strategy outperformed the S&P 500® and significantly exceeded the Russell 1000 Value® Index in Q3 2025 [1] - The Matrix Dividend Income (MDI) portfolio showed robust performance over nine months ending September 30, with gains in the low teens despite lagging behind the Russell 1000 Value® Index and S&P 500 in the last three months [1] Company Analysis: Lockheed Martin Corporation (NYSE:LMT) - Lockheed Martin is the largest U.S. defense contractor, supplying advanced military systems to the U.S. Government and allies [3] - The stock experienced a one-month return of -3.53% and a 52-week loss of 13.64%, closing at $468.26 with a market capitalization of $109.322 billion on November 20, 2025 [2] - The company faced challenges in 2025, including losing a contract to Boeing for next-generation fighter jets and an unexpected charge of $1.6 billion related to its Aeronautics and Canadian helicopter programs [3] - Despite these setbacks, there is optimism for a rebound as the company reiterated its full-year earnings guidance and has a history of dividend increases, yielding 3.1% at the time of purchase [3] Investment Sentiment - Lockheed Martin is not among the 30 most popular stocks among hedge funds, with 73 hedge fund portfolios holding the stock at the end of Q2 2025, an increase from 68 in the previous quarter [4] - While Lockheed Martin is recognized for its potential, certain AI stocks are viewed as having greater upside potential and less downside risk [4]

Core Viewpoint - Soleno Therapeutics Inc. is identified as a promising investment opportunity despite recent market challenges, with an Outperform rating and a price target of $75 set by Wolfe Research analyst Kalpit Patel [1][3]. Financial Performance - In Q3 2025, Soleno Therapeutics reported a net income of $26 million, significantly boosted by increased sales of its drug ViCAT XR, with total net revenue more than doubling from Q2 to reach $66 million [3]. - The company has achieved broad market adoption for ViCAT XR, securing coverage for approximately 132 million lives and currently supporting 764 active patients with reimbursed claims [3]. Market Outlook - Patel's analysis indicates a favorable directional trend for patient utilization over the next 1-2 years, which contradicts the market's concerns regarding a slowdown in new patient starts [2][3]. - The recent weakness in the company's stock is attributed to perceived safety concerns related to the slowdown, which Patel considers to be exaggerated [1][2].

Group 1 - Acadia Healthcare Company Inc. is considered a cheap stock to buy according to analysts, with KeyBanc lowering its price target to $30 from $35 while maintaining an Overweight rating [1][3] - In Q3 2025, Acadia Healthcare reported a revenue increase of 4.4%, totaling $851.6 million, supported by a 3% growth in same facility admissions [2][3] - The company's adjusted EBITDA for Q3 decreased to $173 million from $194.3 million in the prior year, leading to a reduction in Adjusted EBITDA guidance for 2025 to a range of $650 to $660 million [3]

Core Insights - BellRing Brands Inc. is considered a cheap stock to buy according to analysts, with Barclays lowering the price target to $32 from $44 while maintaining an Overweight rating [1] Financial Performance - BellRing Brands concluded FY2025 with a 16% year-over-year increase in net sales, achieving $648.20 million in revenue for Q4, which represents a 17% year-over-year rise [2][3] - The flagship Premier Protein brand experienced a 15% growth in Q4 net sales, contributing to a 14% growth in ready-to-drink shake sales, with consumption increasing by 20% [3] Future Outlook - For FY2026, BellRing Brands provided net sales guidance projecting growth between 4% to 8%, while acknowledging a potentially softer Q1 in fiscal 2026 due to specific dynamics but expects acceleration thereafter [3] Product Offering - BellRing Brands offers a variety of nutrition products in the US, including ready-to-drink protein shakes, other RTD beverages, protein powders, and nutrition bars, primarily under the Premier Protein and Dymatize brands [4]

Core Viewpoint - B2Gold Corp (NYSE:BTG) is recognized as a strong mid-cap stock by hedge funds, with a recent Hold rating and a $5 price target from RBC Capital following impressive third-quarter results driven by increased gold production and higher prices [1][2]. Financial Performance - B2Gold achieved a total gold production of 254,369 ounces, exceeding production targets from its Fekola, Masbate, and Otjikoto mines [2]. - Revenue for the third quarter surged to $782.948 million, a significant increase from $448.229 million in the same quarter last year [2]. - The company reported a net income of $23.123 million in the third quarter, a turnaround from a net loss of $631.032 million in the same quarter of the previous year [3]. Earnings and Dividends - B2Gold delivered earnings per share of $0.01, improving from a loss per share of $0.48 in the same quarter last year [3]. - The board of directors approved a quarterly dividend of $0.02 per share, payable on December 15 to shareholders of record as of December 2, 2025 [4]. Financial Position - The company exited the third quarter with a strong financial position, holding $367 million in cash and cash equivalents [4]. Company Overview - B2Gold is a global, low-cost gold miner with three open-pit mines located in Mali, Namibia, and the Philippines, along with exploration projects across four continents [5]. - The company's revenue is entirely derived from gold sales, with operations including Fekola, Masbate, Otjikoto, and other development properties [5].